The Pipeline Blog

In The Pipeline Blog, we aim to discuss a variety of medical and regulatory affairs topics.

  • Symbravo: A Novel Combinational Therapeutic to Alleviate Migraines

    Author: Colin McArdle Editor: Michaela Price, PhD Although typically mischaracterized as just a ‘strong headache’, migraines are a chronic neurological disorder that affect approximately 15% of people worldwide.1 While symptoms are heterogeneous between individuals, migraine attacks typically present with extreme … Read more

  • Ohtuvayre: A New Treatment for Chronic Obstructive Pulmonary Disease (COPD)

    Author: Michaela Price, PhD Editor: Sy’Keria Garrison Today, we will be discussing chronic obstructive pulmonary disease (COPD) and a new COPD treatment called Ohtuvayre (ensifentrine), which was approved on June 26, 2024 by the Food and Drug Administration (FDA) in … Read more

  • Targeting the Dopamine System to Alleviate Chorea in Huntington’s Disease  

    Writer: Colin McArdle Editor: Pari Dhayagude Huntington’s Disease (HD) is the most common inherited neurodegenerative disorder, affecting approximately 30,000 people nationwide.1 HD is a multimodal disorder characterized by a wide array of symptoms that are defined by motor impairments, such … Read more

  • Amyloid-beta immunotherapy: the future for Alzheimer’s therapeutics?

    Writer: Colin McArdle Editor: Misha Fini Approximately 7.2 million Americans over the age of 65 are living with the most common form of dementia – Alzheimer’s disease (AD). Affecting 1 in 9 older adults, AD has increasingly become a financial … Read more

  • Zurzuvae: Novel Medication for Postpartum Depression

    Author: Caryssa Drinkuth Editor: Macy Osborne-Frazier Postpartum depression (PPD) is a serious and potentially life-threatening condition affecting women in their third trimester and up to 12 months after childbirth. Despite affecting 10 to 20 percent of women that have recently … Read more

  • Pembrolizumab and the Treatment of Endometrial Cancer

    Author: Macy Osborne-Frazier Editor: Anna Goddard This article will cover the use of the immune checkpoint inhibitor (ICI)  pembrolizumab to treat endometrial cancer (EC). This drug, developed by Merck and sold under the brand name KEYTRUDA, was originally approved to … Read more

  • The Current Cystic Fibrosis Treatment Landscape and the Emergence of mRNA Therapy to Improve Outcomes for All

    Author: Misha Fini Editor: Morgan McCullough  What is Cystic Fibrosis? Cystic fibrosis (CF) is a genetic disease caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The CFTR protein resides on the apical surface … Read more

  • Zepbound: A Potential Breakthrough in Obstructive Sleep Apnea Management

    Author: Pari Dhayagude Editor: Sarah Sizer, PhD Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by recurrent episodes of complete or partial upper airway collapse, leading to abnormal breathing and oxygen desaturation during sleep.1 OSA affects an … Read more

  • Datroway and Metastatic (Stage IV) HR+/HER2- Breast Cancer

    Author: Sarah Sizer, Ph.D. Editor: Kylie VanDerMolen This article will describe Datroway (datopotamab deruxtecan-dlnk), an antibody-drug conjugate (ADC) developed by the pharmaceutical companies AstraZeneca and Daiichi Sankyo. In January 2025, the Food and Drug Administration (FDA) approved Datroway for the … Read more

  • Duvyzat: A Treatment for Duchenne Muscular Dystrophy

    Author: Michaela Price, PhD Editor: Rachel VanKeulen-Miller Today, we will discuss the histone deacetylase inhibitor Duvyzat (givinostat). In March 2024, the U.S. Food and Drug Administration (FDA) approved Duvyzat as the first nonsteroidal drug to treat Duchenne muscular dystrophy (DMD).1 Key … Read more